Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-26-034807
Filing Date
2026-03-26
Accepted
2026-03-26 17:00:06
Documents
11
Period of Report
2025-11-26
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO.1 TO FORM 8-K ea028303901-8ka_actinium.htm   iXBRL 8-K/A 23330
  Complete submission text file 0001213900-26-034807.txt   194902

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE atnm-20251126.xsd EX-101.SCH 3032
3 XBRL LABEL FILE atnm-20251126_lab.xml EX-101.LAB 34915
4 XBRL PRESENTATION FILE atnm-20251126_pre.xml EX-101.PRE 22800
14 EXTRACTED XBRL INSTANCE DOCUMENT ea028303901-8ka_actinium_htm.xml XML 4323
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36374 | Film No.: 26799123
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)